Recent Progress of the Membrane Palmitoylated Protein (MPP)

Mycoplasma pneumoniae (MP) is a common pathogen that causes acquired pneumonia. MPP is a relatively common respiratory disease, which can be spread through droplets and direct contact in crowded environments. Smokers, infants and people with low immunity are high-risk groups, and the incidence of MPP is increasing year by year under the influence of environmental factors and impaired immune function. Understanding its pathogenesis and identifying predictive biomarkers, while assisting blood or imaging tests, is one of the hot spots of clinicians' attention. At the same time, comprehensive measures should be adopted for the treatment of MPP, because although the disease is often considered to be a self-limiting disease, with the in-depth study of the disease, it is found that drug-resistant mycoplasma pneumoniae strains are gradually increasing, the incidence of severe or refractory mycoplasma pneumoniae pneumonia is also increasing, and the difficulty of clinical treatment is also increasing. This text will talk about the history of MMP and the common symptoms and signs associated with the infection, including cough, fever, sore throat, fatigue, and other respiratory symptoms. Also, it covers the diagnostic methods used to identify MMP. Finally,this paper discuss the efficacy of different treatment options, including antibiotics commonly used to treat MMP, covering the safety of these treatments, including any potential side effects or contraindications. Additionally, it explores the potential resistance of MMP to different antibiotics and how this resistance might affect treatment outcomes.